Search the Newsreel

Exelixis Inc (EXEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Exelixis Inc (EXEL), categorizing it by business segments and geographical regions. CABOMETYX is highlighted as the dominant revenue source, contributing over 91% of the total, followed by license revenues. The United States accounts for the vast …

Exelixis Inc (EXEL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Exelixis Inc (EXEL) shareholder structure, detailing major institutional holdings and shareholder types. It lists top shareholders like BlackRock and Farallon Capital, their proportion of shares, and changes in their holdings over time. The document also includes a historical …

Delixy Holdings Ltd (DLXY) Income Statement

This TradingKey.com page provides the income statement for Delixy Holdings Ltd (DLXY), offering insights into its financial performance. It includes key financial metrics for 2025, such as total revenue of $307.75M, net income of -$4.46M, and an operating income of -$4.53M. The page also …

TLX|Telix Pharmaceuticals Ltd|Price:12.310|Chg%:+0.340

Telix Pharmaceuticals Ltd (TLX) Institutional Confidence

This article focuses on the institutional confidence in Telix Pharmaceuticals Ltd (TLX), displaying recent shareholder activity. It lists several investment firms, including Portland Investment Counsel Inc. and Lazard Asset Management, L.L.C., along with their current shares held and the percentage change in their holdings. …

DLXY|Delixy Holdings Ltd|Price:0.448|Chg%:-0.059

This article provides financial details for Delixy Holdings Ltd (DLXY), including its current stock price, market capitalization, and recent earnings data. It highlights key financial indicators from the FY2025 earnings report, such as revenue, EPS, assets, liabilities, and various ratios like debt-to-assets and return …

Helix Energy Solutions Group, Inc. Revenue Breakdown – NYSE:HLX

Helix Energy Solutions Group, Inc. (HLX) reported a total revenue of $1.29 billion USD last year. The Well Intervention segment was its top-performing segment, generating $729.37 million USD. The United States was the largest contributor to revenue, accounting for $494.54 million USD.

Elixinol Wellness Ltd Revenue Breakdown – ASX:EXL

Helix Energy Solutions Group Inc (HLX) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides dividend and stock split information for Helix Energy Solutions Group Inc (HLX). It notes that a total of 0.00 USD has been distributed in dividends over the past five years and indicates that no specific dividend data is available in the …

EXEL|Exelixis Inc|Price:55.370|Chg%:-0.280

Exelixis Inc (EXEL) is an oncology company with strong fundamentals and high growth potential, though its stock performance has been average over the past month. The company's valuation is considered fair, and it has a high institutional ownership. Analysts generally rate EXEL as a …

Telix Pharmaceuticals Ltd. (TLX) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of January 9, 2026 Deadline

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) on behalf of investors who purchased securities between February 21, 2025, and August 28, 2025. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements regarding …

HLX|Helix Energy Solutions Group Inc|Price:9.910|Chg%:+0.215

Helix Energy Solutions Group Inc. (HLX) is an international offshore energy services company specializing in well intervention, robotics, and decommissioning. The company's stock shows "fairly valued" fundamentals and good growth potential, with strong institutional ownership. Analysts rate HLX as a "Buy" with a target …

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

Telix Pharmaceuticals Limited reported Q2 2026 group revenue of US$247 million, a 7% increase quarter-over-quarter and 21% year-over-year, driven by strong growth in its Precision Medicine segment. The company expects full-year 2026 revenue to exceed US$1 billion and has updated its R&D expenditure guidance …

What Telix Pharmaceuticals (ASX:TLX)'s Upgraded US$1 Billion FY26 Outlook Means For Shareholders

Telix Pharmaceuticals (ASX:TLX) recently reported positive clinical data, initiated a Phase 3 trial, and raised its FY26 revenue outlook to over US$1 billion. These developments signify strong progress in its radiopharmaceutical pipeline and validate its theranostic business model. The upgraded guidance reinforces the company's …

EXEL Maintained by Morgan Stanley -- Price Target Raised to $53

Morgan Stanley has maintained an Equal-Weight rating on Exelixis (EXEL) while raising its price target from $50.00 to $53.00, an increase of 6%. Despite this cautious optimism, GuruFocus assesses EXEL as 29.1% overvalued with a GF Value™ of $42.86 against its current price of …

Telix Pharmaceuticals (TLX) Gains Ground: Approaching Key Resistance at $11.04 - Mean Reversion Trade

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

Exelixis, Inc. announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The company will also host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss these results and …

Telix Pharmaceuticals (TLX) Status Update Summary

Telix Pharmaceuticals provided a status update on its urology therapeutic strategy and pipeline, focusing on prostate, kidney, and bladder cancers. The company highlighted its comprehensive portfolio, including lead asset TLX591 in phase III for prostate cancer, and next-generation therapies. Telix also discussed its kidney …

Delixy Holdings (NASDAQ: DLXY) reports material control weaknesses

Delixy Holdings Ltd filed an amendment to its 2025 annual report, revising disclosures on controls and procedures due to material weaknesses in internal control over financial reporting identified using the 2013 COSO Framework. Despite these weaknesses, management asserts that the consolidated financial statements fairly …

Exelixis sets Aug. 5 webcast to discuss Q2 results and update

Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?

Study Tests Imaging to Select Patients for Telix Prostate Therapy

Telix Pharmaceuticals announced the publication of results from its Phase 1 ProstACT SELECT study in the journal Cancers. The study evaluated the use of 68Ga-PSMA-PET imaging to select patients for TLX591-Tx, a PSMA-targeting radio antibody-drug conjugate for advanced metastatic castration-resistant prostate cancer (mCRPC). The …

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Telix Pharmaceuticals announced the publication of results from its ProstACT SELECT study in Cancers journal. The study confirmed the utility of 68Ga (gallium)-PSMA-PET imaging for selecting patients for TLX591-Tx therapy, a PSMA-targeting rADC therapy candidate for advanced metastatic prostate cancer. Results highlighted the therapy's …

475,000 Private Placement Shares of Helix Acquisition Corp. III are subject to a Lock-Up Agreement Ending on 22-JUL-2026.

475,000 Private Placement Shares of Helix Acquisition Corp. III are subject to a lock-up agreement that will end on July 22, 2026. These shares were under lockup for 181 days, starting from January 22, 2026. The initial shareholders, officers, and directors agreed not to …

Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal

Telix Pharmaceuticals reported strong Q2 2026 revenue of US$247 million, a 21% year-over-year increase, with Precision Medicine revenue up 30%. The company expects FY 2026 revenue to exceed US$1 billion and has increased its R&D spending guidance to accelerate late-stage programs. Telix also announced …

Felix Gold Limited (ASX:FXG): Why the Antimony-and-Gold Explorer Is Back in the Spotlight

Telix Pharmaceuticals: Q2 2026 revenue jumps 21%

Telix Pharmaceuticals (TLX) Q2 2026 TU earnings summary

Telix Pharmaceuticals (TLX) reported Q2 2026 group revenue of US $247 million, a 21% year-over-year increase, with Precision Medicine revenue up 30% YoY. The company reached FDA alignment for its ProstACT Global Phase 3 study and initiated a strategic collaboration with Regeneron, receiving a …

Telix Pharmaceuticals reports Q2 revenue of US$247M

Telix Pharmaceuticals (ASX:TLX) reported US$247 million in group revenue for Q2 2026, marking a 21% increase year-over-year. This growth was primarily driven by strong performance in its precision medicine unit, particularly Gozellix and the PSMA imaging portfolio. The company projects full-year 2026 revenue to …

Telix Q2 revenue rises 21% YoY to US$247 million

Telix Pharmaceuticals Limited announced a 21% year-over-year increase in Q2 2026 revenue, reaching US$247 million, primarily driven by Precision Medicine growth. The company has revised its FY 2026 revenue outlook to over US$1 billion and increased its R&D guidance to US$230 million–US$270 million. Key …

Telix Pharmaceuticals posts 21% increase in Q2 revenue, tracks top end of full year guidance

Telix Pharmaceuticals announced a 21% year-on-year increase in Q2 group revenue to USD247 million, driven by strong demand in its prostate imaging portfolio. The company is on track to meet the higher end of its full-year guidance, forecasting revenue in excess of USD1 billion, …

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has initiated its Phase 3 LUTEON trial for TLX250-Tx, a targeted radiopharmaceutical therapy for relapsed or recurrent clear cell renal cell carcinoma (ccRCC), by dosing the first patient. This study is notable as the first Phase 3 radiopharmaceutical …

ASX Preview: Australian Shares to Fall as Oil Gains on Middle East Tensions; Telix Pharmaceuticals Posts Higher Q2 Revenue

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Exelixis (EXEL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to …

Telix Pharmaceuticals trails ASX 200 by 8.3 points; Japan remains beyond guidance

Telix Pharmaceuticals (ASX:TLX; NASDAQ:TLX) underperformed the ASX 200, seeing an 8.36% decline over five sessions, including a 4.48% drop on Friday. This occurred despite progress in its Japan Phase 3 enrollment for Illuccix, which is still awaiting conditional approval and is excluded from Telix's …

Helix Energy Solutions stock holds steady after latest results

Helix Energy Solutions Group, Inc. (HLX) stock is being reviewed based on its latest reported revenue, earnings, and balance sheet trends. The article emphasizes that investor focus should be on the company's operating results, balance sheet, and investor relations channels for the most accurate …